tm logo
QUOTIENT
FORMALIZED

on 28 Aug 2024

Last Applicant/ Owned by

QUOTIENT THERAPEUTICS INC.

55 Cambridge Parkway, Suite 800ECambridge MA 02142

US

Serial Number

2346423 filed on 17th May 2024

QUOTIENT

Trademark usage description

pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gas Read More

Classification Information


Class [005]
Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical compositions comprised of small molecules for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases.


Classification kind code

12

Mark Details


Serial Number

2346423

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 257
on 29th Aug 2024
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 28th Aug 2024
Created
Submitted for opposition 31
on 28th Aug 2024
Formalized
Submitted for opposition 228
on 17th May 2024
International Registration
Submitted for opposition 30
on 17th May 2024
Filed